FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
Based on a completed FDA review of a large randomized safety clinical trial, the FDA has concluded there is an increased risk of serious heart-related events such as… read more.
